Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

about

Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.

P2860

Q36955295-E0F184AC-1D5F-4CA8-8EC3-812F8A77E1E6 Q51292343-10636569-4780-46EA-915E-E5CA5B0DCFEF

P2860

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

Item

http://www.wikidata.org/entity/Q43164937

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@en

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@nl

type

Item

label

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@en

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@nl

prefLabel

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@en

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

@nl

P1476

Endogenous elevation of plasma cholecystokinin does not prevent gallstones

@en

P2093

Brian E Fee

http://www.w3.org/2001/XMLSchema#string

David Q-H Wang

http://www.w3.org/2001/XMLSchema#string

Joelle M-J Romac

http://www.w3.org/2001/XMLSchema#string

Rafiq A Shahid

http://www.w3.org/2001/XMLSchema#string

Rodger A Liddle

http://www.w3.org/2001/XMLSchema#string

Steven R Vigna

http://www.w3.org/2001/XMLSchema#string

P2860

Transgenic expression of pancreatic secretory trypsin inhibitor-I ameliorates secretagogue-induced pancreatitis in mice

Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion

Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice.

Association of caveolin-3 and cholecystokinin A receptor with cholesterol gallstone disease in mice

Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle.

Regulation of cholecystokinin secretion by intraluminal releasing factors.

Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Gallbladder motor function, plasma cholecystokinin and cholecystokinin receptor of gallbladder in cholesterol stone patients.

Pancreatic secretory trypsin inhibitor I reduces the severity of chronic pancreatitis in mice overexpressing interleukin-1β in the pancreas.

Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease.

P304

237-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ECI.12400

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shannon J. McCall

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25641074

http://www.w3.org/2001/XMLSchema#string

P921

Cholecystokinin

P932

4342269

http://www.w3.org/2001/XMLSchema#string

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

about

P2860

P2860

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932